Compare Expensify Inc (EXFY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Novartis AG — how do they compare? Expensify Inc trades at $2.43 (market cap $208.82M), while Novartis AG trades at $143.84 (market cap $268.57B). The key difference: Novartis AG is far larger — about 1286.1× Expensify Inc's market cap, and Novartis AG pays a 3.31% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Novartis AG for 82 Days on average.
| EXFY | NVS | |
|---|---|---|
Market Cap | $208.82M | $268.57B |
Volume | 456,102 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $2.72 | $168.62 |
52-Week Low | $0.75 | $121.80 |
Typical Hold Time | 41 Days | 82 Days |
Enterprise Value | $148.44M | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.37, up 4.41% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with a high P/E ratio of 258.82 but improving cash flow trends, with Q2 2026 earnings beating expectations. Recent news highlights strategic integrations with AI-native ERP platforms and European expansion of its corporate card offering, signaling growth initiatives.
The outlook remains speculative with analyst consensus bullish (50% buy ratings) and a $13.75 price target, but negative net income margins and competitive pressures pose risks. Investment opportunity hinges on successful execution of AI-driven products and international growth, while downside risks include sustained profitability challenges and market volatility.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
